Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003187 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00003187 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 19 participants.
The verdict
NCT00003187, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. PURPOSE: Randomized phase II/III trial to compare the effectiveness of conventional bone marrow transplantation with T cell-depleted bone marrow transplantation in treating patients who have leukemia, myelodysplasia, or lymphoblastic lymphoma.
Interventions
- DRUG cyclophosphamide
- DRUG methotrexate
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 1995-05 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003187
The ClinicalTrials.gov registry entry for NCT00003187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003187 about?
NCT00003187 is a clinical study titled "Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma". RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the d...
What is the current status of trial NCT00003187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 1995-05. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00003187?
The interventions under investigation include: cyclophosphamide (DRUG), methotrexate (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00003187?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.